Taxol Adjuvant Indication Should Refer To Receptor Status Effect On Efficacy
Executive Summary
The indication for Bristol-Myers Squibb's Taxol should refer physicians to the "clinical studies" section of labeling for information about receptor subgroup analyses, FDA's Oncologic Drugs Advisory Committee said Sept. 17 in recommending sequential administration of Taxol (paclitaxel) following chemotherapy for node-positive breast cancer.